market opportunity

• The worldwide bariatric surgery market (gastric band and balloon segments only) is approximately $290 million, growing at a rate of approximately 50 percent annually.⁽¹⁾
• Allergan’s market share is approximately 80 to 85 percent.⁽¹⁾
• By 2010, the market for surgery and medical devices to treat obesity is anticipated to grow to $1.7 billion (including gastric bypass).⁽²⁾

Over the last 50 years obesity has emerged as a major health crisis, affecting approximately 400 million adults worldwide.⁽³⁾ In response to this growing global epidemic, Allergan develops and markets products that provide doctors and patients with healthier, minimally invasive long-term options in the maintenance of a healthy weight.

BIB™ Intragastric Balloon

The BIB™ System is a non-surgical alternative for the treatment of obesity made of durable, elastic, high-quality silicone. It is endoscopically placed and inflated with saline solution, and works by partially filling the stomach to induce a feeling of fullness, thereby reducing the patient’s intake of food. The BIB™ System is broadly approved worldwide; however, it is not currently available in the United States.

LAP-BAND^® and LAP-BAND AP^® Adjustable Gastric Banding Systems

In June 2007, Allergan launched the LAP-BAND AP^® System in the United States, which is an evolution of the LAP-BAND^® System. The LAP-BAND^® System is the first FDA-approved adjustable gastric band for use in weight reduction for severely obese adults with a Body Mass Index (BMI) of 40 or more, or for adults with a BMI of at least 35 plus at least one severe obesity-related health condition, such as Type 2 diabetes, hypertension or asthma. Since its global introduction in 1993, the LAP-BAND^® System has been used in more than 350,000 procedures worldwide.